The Osteoporosis Risk Assessment Instrument (ORAI): Difference between revisions

(Created page with "<div class="editorbox"> '''Original Editor '''- Your name will be added here if you created the original content for this page. '''Top Contributors''' - {{Special:Contributors/...")
 
m (Removed rss feed)
 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
<div class="editorbox">
<div class="editorbox">
'''Original Editor '''- Your name will be added here if you created the original content for this page.
'''Original Editor '''- [[User:Ajay Upadhyay|Ajay Upadhyay]]


'''Top Contributors''' - {{Special:Contributors/{{FULLPAGENAME}}}} &nbsp;  
'''Top Contributors''' - {{Special:Contributors/{{FULLPAGENAME}}}} &nbsp;  
</div>  
</div>  
== Objective<br>  ==
== Objective<br>  ==


The Osteoporosis Risk Assessment Instrument (ORIA) can be used to select women for bone densitometry. This can help reduce the number of women who are screened so that resources can be used for those at risk. The authors are from several medical institutions in Toronto including the University of Toronto.
The Osteoporosis Risk Assessment Instrument (ORIA) can be used to select women for bone densitometry. This can help reduce the number of women who are screened so that resources can be used for those at risk. The authors are from several medical institutions in Toronto including the University of Toronto.  


== Patient selection<br>  ==
== Patient selection<br>  ==


Canadian women aged >= 45 years of age (osteoporosis has a prevalence < 1% in women < 45 years)
Canadian women aged &gt;= 45 years of age (osteoporosis has a prevalence &lt; 1% in women &lt; 45 years)  


== Exclusion criteria  ==
== Exclusion criteria  ==


women with a diagnosis of osteoporosis or taking bone active medications other than estrogen-progesterone (calcitonin, biphosphonates, fluoride).
women with a diagnosis of osteoporosis or taking bone active medications other than estrogen-progesterone (calcitonin, biphosphonates, fluoride).  


== Parameters<br>  ==
== Parameters<br>  ==


(1) age in years <br>
(1) age in years <br> (2) weight in kilograms <br> (3) current estrogen use <br>
(2) weight in kilograms <br>
 
(3) current estrogen use <br>
[[Image:ORAI.png|left]]
 
<br>
 
<br>
 
<br>
 
<br>
 
<br>
 
<br>
 
<br>  


ORIA score = (SUM(points for all 3 parameters)<br>
<br>  


== Interpretation<br> ==
<br>  


• minimum score: 0 <br>
<br>  
• maximum score: 26 <br>
• Bone densitometry should be done if the woman has a total score >= 9. <br>


== Performance<br> ==
<br>  


• The sensitivity was 93.3% and specificity 46.4% for identifying Canadian women with low bone density. The sensitivity was 94.4% for women with osteoporosis.
<br>


<br>
<br>
<br>
<br>
ORIA score = (SUM(points for all 3 parameters)<br>
== Interpretation<br>  ==
• minimum score: 0 <br> • maximum score: 26 <br> • Bone densitometry should be done if the woman has a total score &gt;= 9. <br>
== Performance<br>  ==
• The sensitivity was 93.3% and specificity 46.4% for identifying Canadian women with low bone density. The sensitivity was 94.4% for women with osteoporosis.
<br>


== Reference<br>  ==
== Reference<br>  ==
Line 39: Line 72:
Cadarette SM, Jaglal SB, et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ (Canadian Medical Assoc J). 2000; 162: 1289-1294.  
Cadarette SM, Jaglal SB, et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ (Canadian Medical Assoc J). 2000; 162: 1289-1294.  


 
<br>  
 
== Recent Related Research (from [http://www.ncbi.nlm.nih.gov/pubmed/ Pubmed])  ==
<div class="researchbox">
<rss>http://www.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1roWqUHnCMOq0KYkEQwgqXsaBJHnEqdekPJeGpUAiHRHmm9IAF|charset=UTF-8|short|max=10</rss>
</div>  


== References  ==
== References  ==
References will automatically be added here, see [[Adding References|adding references tutorial]].


<references />.
<references />.

Latest revision as of 15:19, 20 July 2019

Original Editor - Ajay Upadhyay

Top Contributors - Ajay Upadhyay, Kim Jackson and WikiSysop  


Objective
[edit | edit source]

The Osteoporosis Risk Assessment Instrument (ORIA) can be used to select women for bone densitometry. This can help reduce the number of women who are screened so that resources can be used for those at risk. The authors are from several medical institutions in Toronto including the University of Toronto.

Patient selection
[edit | edit source]

Canadian women aged >= 45 years of age (osteoporosis has a prevalence < 1% in women < 45 years)

Exclusion criteria[edit | edit source]

women with a diagnosis of osteoporosis or taking bone active medications other than estrogen-progesterone (calcitonin, biphosphonates, fluoride).

Parameters
[edit | edit source]

(1) age in years
(2) weight in kilograms
(3) current estrogen use

ORAI.png

















ORIA score = (SUM(points for all 3 parameters)

Interpretation
[edit | edit source]

• minimum score: 0
• maximum score: 26
• Bone densitometry should be done if the woman has a total score >= 9.

Performance
[edit | edit source]

• The sensitivity was 93.3% and specificity 46.4% for identifying Canadian women with low bone density. The sensitivity was 94.4% for women with osteoporosis.


Reference
[edit | edit source]

Cadarette SM, Jaglal SB, et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ (Canadian Medical Assoc J). 2000; 162: 1289-1294.


References[edit | edit source]

.